Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

The present invention relates to the field of medical diagnostics. In particular, it relates to methods and kits for determining treatment efficacy of allergen immunotherapy, and for measuring or detecting biomarkers in a subject undergoing allergen immunotherapy. For example, the invention provides a method of determining efficacy of an allergen immunotherapy in a subject, the method comprising: providing a first sample obtained from a subject before receiving allergen immunotherapy; providing a second sample obtained from the subject who has received, or who is receiving, allergen immunotherapy; wherein the first and second samples comprise B-cells; and determining the level or amount of one or more biomarkers in B-cells, preferably allergen-specific B-cells, in the first and second samples, wherein the biomarkers are selected from the group consisting of IgE, CD29, CD69, IL13R, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CDIc, CD23, and IL4R; wherein an increase in the level or amount of one or more biomarkers selected from IgE, CD29, IL13R, CD99, FCRL3, FCRL2, SIGLEC10, CD1c, CD23, and IL4R in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject, and/or wherein a decrease in the level or amount of one or more biomarkers selected from CD69, IgD, CXCR4, FCRL3, FCRL2, FCRL5, CD1c, CD23, IL4R in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject.

The disclosure provides for methods and compositions that target the interaction of V/1 integrin and monomeric MPO in ovarian cancer and other hyperproliferative disorders. Accordingly, aspects of the disclosure relate to a method for treating endometrial or ovarian hyperproliferative disorders in a subject, the method comprising administration of an inhibitor of V/1 integrin, an MPO inhibitor, and/or the combination of an V/1 integrin and an MPO inhibitor to the subject. In some aspects, the hyperproliferative disorder comprises ovarian cancer or epithelial ovarian cancer. In some aspects, the hyperproliferative disorder comprises endometriosis.

This application is directed to methods and compositions related to the treatment and diagnosis of adenocarcinomas, such as adenoid cystic carcinoma (ACC). The methods and compositions related to the use of CD49f, TP63, and/or KIT/CD117 cell-surface markers for subtyping the cancer cells. One method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to inhibit the differentiation of myoepithelial-like cells into ductal-like cells. Another method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to selectively reduce the viability of ductal-like cells.